Freebird Partners LP - Apr 3, 2023 Form 3 Insider Report for Eterna Therapeutics Inc. (ERNA)

Role: 10%+ Owner
Signature: Freebird Partners LP, By: Freebird Investments LLC, its general partner, By: /s/ Curtis W. Huff, Chairman and President
Stock symbol: ERNA
Transactions as of: Apr 3, 2023
Transactions value $: $0
Form type: 3
Date filed: 4/4/2023, 05:03 PM
Next filing: Jul 18, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ERNA	Common Stock, par value $0.005 per share						273K	Apr 3, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ERNA	Common Stock Purchase Warrant							Apr 3, 2023	Common Stock, par value $0.005 per share	425K	$3.28	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This report is filed jointly by Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.0005 of Eterna Therapeutics Inc. (the "Company"). These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners.
F2	Pursuant to that certain Securities Purchase Agreement, as announced in the Issuer's Current Report on Form 8-K filed with the SEC on November 25, 2022, the Company issued that certain Common Stock Purchase Warrant ("Warrant") to Freebird Partners LP on December 2, 2022, in substantially the form as the form of warrant filed as Exhibit 10.1 to the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on December 2, 2022. The Warrant becomes exercisable on June 2, 2023, and may be exercised through June 2, 2028, at an exercise price of $3.28 per share of Common Stock.

Content

This report is filed jointly by Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.0005 of Eterna Therapeutics Inc. (the "Company"). These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners.

Pursuant to that certain Securities Purchase Agreement, as announced in the Issuer's Current Report on Form 8-K filed with the SEC on November 25, 2022, the Company issued that certain Common Stock Purchase Warrant ("Warrant") to Freebird Partners LP on December 2, 2022, in substantially the form as the form of warrant filed as Exhibit 10.1 to the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on December 2, 2022. The Warrant becomes exercisable on June 2, 2023, and may be exercised through June 2, 2028, at an exercise price of $3.28 per share of Common Stock.